There are no blood tests or useful imaging methods that can adequately and routinely detect most types of cancers when they are at their earliest and most curable stage. MBCI has the answer to this problem!
Monoclonal antibodies (MAbs) are one of the most useful biomolecules ever discovered!
From my understanding, this all comes about by taking a piece of the persons cancer and then they clone it and form antibodies against the cancer to help the body "recognize" the cancer and fight the diseased cells. They then inject the antibodies and this in theory then gives the body a chance to kill the cancer cells using its own immune system. This has started to become a HUGE breakthrough and story across the world and MBCI is position perfectly to capitalize on it!
The challenge of producing antibodies against specific cancer antigens has eluded scientists for many decades. Modern technologies for designing antibodies against a known disease require both the identification and availability of the antigens which characterize the disease. The putative tumor-specific antigens (TSA), presumed to exist on cancer cells, have eluded identification, thus making the generation of antibodies against them through current technologies virtually impossible.
Classic Hybridoma technology is based on the generation of immortal “hybrid cells” (hybridoma), which follows the fusion of antibody-producing B-cells with myeloma tumor cells. Each hybridoma continuously “manufactures” a single type of (“monoclonal”) antibody. MBCI has "re-engineered" the classic hybridoma technology into a highly efficient and optimized one, overcoming the inherent limitations of the former, yet exploits its benefits!
MBCI hybridoma technology exhibits several important advantages over competing technologies:
- Prior identity of cancer antigen(s) is not required for generating Mabs against these antigens. MBCI’s approach to creating anti-cancer Mabs is unbiased and enhances the discovery of new cancer markers.
- Antigens are preserved in their natural conformations; the resulting Mabs are able to better recognize and bind more selectively to tumor cells.
- Unlimited quantities of antibodies produced against a selected cancer target. A large number of antibodies is the key factor for obtaining an antibody repertoire which would exhibit both tumor specificity and tumor "universality".
MBCI has successfully generated hybridoma libraries for three different cancers that produce, respectively, antibodies to melanoma, to an aggressive form of prostate cancer and to ovarian carcinoma. These antibodies have been shown to be specific and "universal" to each cancer respectively, i.e. they recognize every cancer from different individuals having that particular disease and do not react with any normal antigen tested so far. These Mabs are the first candidates for the development of novel diagnostic tools, imaging agents and drugs to treat the corresponding cancers.
MBCI’s Market Potential and Opportunity is Unbelievable!
View message 
Comment on this message 
Receive as RSS 
del.icio.us 
Digg 
reddit 
Facebook 
StumbleUpon 
